Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 23Nasopharyngeal Carcinoma 23Stomach Neoplasms 21Esophageal Squamous Cell Carcinoma 19Esophageal Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 14Uterine Cervical Neoplasms 12Colorectal Neoplasms 12Sarcoma 10Pancreatic Neoplasms 9Lung Neoplasms 9Recurrence 7Neoplasm Metastasis 7Melanoma 6Hodgkin Disease 6Cholangiocarcinoma 6Liver Neoplasms 5Biliary Tract Neoplasms 5Small Cell Lung Carcinoma 4Osteosarcoma 4Neoplasms 4Advanced Solid Tumor 4Advanced Gastric Cancer 4Solid Tumor 3Respiratory Tract Diseases 3Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

toripalimab 1camrelizumab 1Radiotherapy 1Paclitaxel 1Injections 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chemotherapy × camrelizumab × Clear all
NCT05821452 2023-04-20

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Fujian Medical University Union Hospital

Phase 2 Unknown
40 enrolled

Chemotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡